title: Response to hepatitis A and B vaccination in pediatric patients with celiac disease.
abstract: OBJECTIVE
  The aim of the study was to evaluate the response to hepatitis A and B vaccinations in pediatric patients with celiac disease (CD).
  
  
  METHODS
  Thirty patients with CD ages 1 to 15 years were compared with 50 healthy age-, sex-, and body mass index-matched controls. Screening for hepatitis A and B serology was carried out before vaccination. Susceptible cases received 20 μg of recombinant DNA vaccine for hepatitis B (0,1, and 6 months) and 720 milliELISA units of inactivated hepatitis A virus (HAV) vaccine (0 and 6 months). Postvaccination serologic evaluation was performed 1 month after the last dose of primary vaccination, 1 month after the booster dose, and once every year during follow-up.
  
  
  RESULTS
  Sixteen patients and 35 controls received hepatitis A vaccine; protective anti-HAV antibodies were developed in 12 (75%) of the patients and all of the controls (75% vs 100%, respectively; 95% confidence interval [CI] 0.47-0.92, P=0.007). Thirty patients and 50 controls received hepatitis B vaccine, and 70% of the patients vs 90% of the controls achieved seroprotection (anti-HBs titers ≥10 mIU/mL) 1 month after primary vaccination (95% CI 0.74-0.90, P=0.03). Four patients were unresponsive to both of the vaccines. The overall seroprotection rates were 96% in controls and 80% in patients after the whole hepatitis B vaccination series (95% CI 0.04-0.18, P=0.04). No significant reduction was observed in antibody response among patients and controls during follow-up period.
  
  
  CONCLUSIONS
  The rate of seroconversion to the hepatitis B virus- and HAV vaccine is lower in patients with CD than in healthy controls.
authors.affiliation: Division of Pediatric Gastroenterology, Department of Pediatrics, Sisli Etfal Training and Research Hospital, Istanbul, Turkey.
authors.forename: Nafiye
authors.initials: N
authors.lastname: Urganci
authors.forename: Derya
authors.initials: D
authors.lastname: Kalyoncu
mesh_terms: D000293:Adolescent; D002446:Celiac Disease / Q000097:blood / Q000276:immunology*; D002648:Child; D002675:Child, Preschool; D005260:Female; D005500:Follow-Up Studies; D035922:Hepatitis A Antibodies / Q000032:analysis; D022362:Hepatitis A Vaccines / Q000276:immunology*; D017957:Hepatitis A Virus, Human / Q000276:immunology; D006510:Hepatitis B Antibodies / Q000032:analysis; D017325:Hepatitis B Vaccines / Q000276:immunology*; D006515:Hepatitis B virus / Q000276:immunology; D006801:Humans; D056724:Immunity, Humoral; D007223:Infant; D008297:Male; D011446:Prospective Studies; D019444:Vaccines, DNA / Q000276:immunology; D015164:Vaccines, Inactivated / Q000276:immunology
chemical_list: D035922:Hepatitis A Antibodies; D022362:Hepatitis A Vaccines; D006510:Hepatitis B Antibodies; D017325:Hepatitis B Vaccines; D019444:Vaccines, DNA; D015164:Vaccines, Inactivated